Clinical Trial Update: Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck [Phase 2]

View source ↗

Summary

Phase 2 trial of docetaxel plus capecitabine as first-line treatment for metastatic squamous cell carcinoma of the head and neck was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Capecitabine (capecitabine)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Hoosier Cancer Research Network | Conditions: Head and Neck Cancer | Phase 2 | Status: TERMINATED